X4 Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we can get started with our next fireside chat. I'm Rosy Liao. I'm a member of the biotech research team at Guggenheim Securities. I'm excited to have X4 Pharmaceuticals with me here today. On stage with me, I have Adam Craig, Executive Chairman. Welcome. Great to have you here.
Thank you, Rosie. Thanks for the invite.
Adam, it's been a little over a year since the new team came into X4. I guess for those less familiar with the story, could you maybe start with a quick overview of the company and perhaps talk about how your prior experience has kind of shaped how you've run the company today?
Yes. Well, thank you. Well, I think the last year has been a period of transformation for X4. The new management team came in August of last year. During that time, we've raised $240 million to finance our work, but we've made a big change to the company. There's been a lot of restructuring. We changed the C-suite. There's been some changes on the board. But the main change is we've become a company that's really 99% focused on the conduct of our phase III pivotal trial in chronic neutropenia, the 4WARD trial. That is the primary focus of the company, and we say to employees, "If you don't come in to the office in the morning and think about what can you do for that trial, then you need to rethink, because that is the main value driver of the company.
Great. Can you talk about what you see as the most important changes you've made to the company so far?
Well, I've mentioned the focus on 4WARD. I think the other thing is the financial discipline. The company before we joined was spending a lot of money. Under the leadership of our CFO, David Kirske, who's with me today, we've really become a disciplined company. We're fortunate enough to have a substantial amount of cash in the bank, but we want to use it wisely, and we want to make sure we have enough cash to commercialize the chronic neutropenia opportunity. Through the discipline David's instilled in the company, we're on target to achieve that goal.
Great. You mentioned your focus on chronic neutropenia currently. You're running a phase III trial, 4WARD. You recently had an FDA meeting where you aligned on resizing the trial a little bit. Can you maybe walk us through the design of the trial and the rationale behind the moves there?
Yeah. The trial is a study of primary chronic neutropenia. That's patients who have neutrophil counts less than 1,000, which is moderate and severe disease. These patients, the patients we enroll on trial, are patients who are symptomatic, so they have to have at least two or more infections in the prior year. That's unfortunately the life of someone with chronic neutropenia. They get multiple infections. It could be in the skin, in the ear, in the lungs, wherever. The trial is a double-blinded placebo-controlled trial where our lead agent, mavorixafor, which is a CXCR4 antagonist, is compared to placebo. As many of you know, patients with chronic neutropenia, some of them take G-CSF. On each arm, it's mavorixafor. For the arms, mavorixafor plus or minus G-CSF, placebo plus or minus G-CSF.
The study is 126 patients, one-to-one randomization, and we have two primary endpoints. The first is a reduction in annualized infection rate over a 12-month period, and the second is an increase of the ANC on at least three occasions over a 12-month period of at least 500 cells per microliter. As I said at the beginning, all our patients have moderate or severe neutropenia, so an ANC less than 1,000. You can see an increase of 500 could be a quite significant change and could lead to a reduction in infection rate.
Great. There hasn't been a lot of innovation in the chronic neutropenia space. I think the last dedicated trial was probably run by Amgen back in the '90s.
I guess, could you talk us through kind of how patients are being treated currently?
Yeah. You're absolutely right. Currently, really, the patients are treated in two ways. With G-CSF, which is only approved for severe neutropenics, it's not approved for moderate neutropenics. It's used on our trial, it's about 37% of patients, and that's what we've seen in our market research as well. Around 35% of patients are on G-CSF. It's used in a huge number of ways. There is no standard of care. Some patients take it weekly, some patients take it daily, and there are different doses. There's no standard of care. The patients we're seeing on study are, in effect, G-CSF refractory because they're not responding to it, because they still have low neutrophil counts. So that illustrates you can be on G-CSF for a while, but you don't necessarily respond to it.
The other concern with G-CSF is it's an injection, it causes bone pain, and there's a risk of long-term malignancy. The median age of patients coming on our trial is 34, and our patients are acutely aware that if they take G-CSF, they could be on it for decades. Therefore, many patients don't want to be on it because of the risk of malignant transformation. The other way patients are treated is with antibiotics, long-term antibiotics as prophylaxis. Some patients will take antibiotics if they're going into a social environment, they're going to work, because the risk of infection is higher. But of course, long-term use of antibiotics is a concern from a resistance point of view and obviously some toxicity. That's it. Then there are some patients who will choose not to have either, watch and wait, so-called watch and wait. So, it really is underserved.
What mavorixafor offers, if it does work and reduce infections and increase ANC count, it will be the first orally available agent in this disease area. So when we spoke to potential prescribers about the drug, there was a lot of enthusiasm for the drug, particularly because it's an oral agent, doesn't so far seem to have a lot of toxicity. It seems to be very manageable. So, we're very excited. Personally, I'm really excited about to offer new therapy in this environment, and if it's an oral agent, I think it will get used extensively.
Great. So, you've guided to the phase III trial completing enrollment this quarter. I guess, how close are we to that being completed?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
